SymBio Pharmaceuticals Limited
SYMQY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2,198 | $382,616 | $264,022 | $553,631 |
| % Growth | -99.4% | 44.9% | -52.3% | – |
| Cost of Goods Sold | $829 | $91,460 | $61,611 | $124,966 |
| Gross Profit | $1,369 | $291,157 | $202,410 | $428,665 |
| % Margin | 62.3% | 76.1% | 76.7% | 77.4% |
| R&D Expenses | $5,891 | $819,369 | $819,369 | $886,236 |
| G&A Expenses | $0 | $0 | $0 | $151,000 |
| SG&A Expenses | $3,516 | $3,554 | $552,213 | $628,397 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $692,000 |
| Other Operating Expenses | $0 | $453,117 | $0 | -$1,000 |
| Operating Expenses | $9,407 | $1,276,040 | $1,371,582 | $1,513,633 |
| Operating Income | -$8,038 | -$984,884 | -$1,169,171 | -$1,084,968 |
| % Margin | -365.7% | -257.4% | -442.8% | -196% |
| Other Income/Exp. Net | -$100 | -$62,811 | -$140,550 | $102,944 |
| Pre-Tax Income | -$8,138 | -$1,047,695 | -$1,309,721 | -$982,024 |
| Tax Expense | -$25 | $14 | $11,759 | $5,952 |
| Net Income | -$8,113 | -$1,047,709 | -$1,321,481 | -$987,976 |
| % Margin | -369.1% | -273.8% | -500.5% | -178.5% |
| EPS | -0.16 | -22.16 | -27.95 | -21.55 |
| % Growth | 99.3% | 20.7% | -29.7% | – |
| EPS Diluted | -0.16 | -22.16 | -27.95 | -21.55 |
| Weighted Avg Shares Out | 49,640 | 47,280 | 47,280 | 45,840 |
| Weighted Avg Shares Out Dil | 49,640 | 47,280 | 47,280 | 45,840 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12 | $4 | $0 | $9,394 |
| Interest Expense | $197 | $357 | $5,523 | $0 |
| Depreciation & Amortization | $0 | $984,829 | $1,169,171 | $24,500 |
| EBITDA | -$7,941 | -$6,894 | -$135,027 | -$1,061,468 |
| % Margin | -361.3% | -1.8% | -51.1% | -191.7% |